Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

BPC-157

Body Protection Compound-157, PL-14736, Pentadecapeptide BPC 157

Quick Stats
Studies 196
Trials 1
Score 3
1993 pubmed

A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC.

Sikirić. P P; Petek. M M; Rucman. R R; Seiwerth. S S; Grabarević. Z Z; Rotkvić. I I; Turković. B B; Jagić. V V; Mildner. B B; Duvnjak. M M

Key Findings

  • A 15‑amino‑acid fragment of the gastric peptide (BPC‑157) shows organ‑protective effects across multiple tissue types in several animal species.
  • Effective doses are extremely low (µg‑ng/kg range) and work via various routes (intraperitoneal, oral, local mucosal).
  • No measurable toxicity or changes in baseline physiological parameters were observed in the studies.

Practical Outcomes

  • For self‑experimenters, BPC‑157 looks promising as a broad‑spectrum protective agent that can be taken in tiny amounts without obvious safety concerns. However, human data are limited, so dosing should start at the low microgram level and be approached cautiously. It may be worth testing for recovery from injuries or chronic stress, but expect modest, not dramatic, effects until more research confirms its benefits.

Summary

BPC‑157 is a tiny peptide found in stomach juice that appears to protect many organs from damage. In animal studies it works at very low doses (micrograms or nanograms per kilogram) when given by injection, orally, or directly to the gut, and it shows benefits even when given after injury. No obvious side effects or toxicity were reported, but the exact way it works is still unclear.

Abstract

The possibility that the stomach, affected by general stress, might initiate a counter-response has not until recently been considered in theories of stress. We suggest that the stomach, as the most sensitive part of the gastrointestinal tract and the largest neuroendocrine organ in the body, is crucial for the initiation of a full stress response against all noxious stress pathology. The end result would be a strong protection of all organs invaded by 'stress'. Consistent with this assumption, this coping response is best explained in terms of 'organoprotection'. Endogenous organoprotectors (eg prostaglandins, somatostatin, dopamine) are proposed as mediators. Such an endogenous counteraction could even be afforded by their suitable application. A new gastric juice peptide, M(r) 40,000, named BPC, was recently isolated. Herein, a 15 amino acid fragment (BPC 157), thought to be essential for its activity, has been fully characterized and investigated. As has been demonstrated for many organoprotective agents using different models of various tissue lesions, despite the poorly understood final mechanism, practically all organ systems appear to benefit from BPC activity. These effects have been achieved in many species using very low dosages (mostly microgram and ng/kg range) after ip, ig, and intramucosal (local) application. The effect was apparent already after one application. Long lasting activity was also demonstrated. BPC was highly effective when applied simultaneously with noxious agents or in already pathological, as well as chronical, conditions. Therefore, it seems that BPC treatment does not share any of the so far known limitations for 'conventional organoprotectors'. No influence on different basal parameters and no toxicity were observed. These findings provide a breakthrough in stress theory. BPC, as a possible endogenous free radical scavenger and organoprotection mediator, could be a useful prototype of a new class of drugs, organoprotective agents.

Study Information

Provider

pubmed

Year

1993

DOI

10.1016/0928-4257(93)90038-u